| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | |
|---|---|---|---|---|
| Total operating expenses | 11,715 | 14,599 | 21,948 | |
| Loss from operations | -11,715 | -14,599 | -21,948 | |
| Interest income | 1,026 | 1,197 | 2,038 | |
| Interest expense | - | 302 | 403 | |
| Other expenses | 538 | - | - | |
| Net loss | -11,227 | -13,704 | -20,313 | |
| Net loss per common share, basic (in dollars per share) | -1.53 | -1.87 | -2.78 | |
| Net loss per common share, diluted (in dollars per share) | -1.53 | -1.87 | -2.78 | |
| Weighted-average shares used to compute net loss per common share, basic (in shares) | 7,323,106 | 7,311,032 | 7,296,222 | |
| Weighted-average shares used to compute net loss per common share, diluted (in shares) | 7,323,106 | 7,311,032 | 7,296,222 | |
Kezar Life Sciences, Inc. (KZR)
Kezar Life Sciences, Inc. (KZR)